Format

Send to

Choose Destination
Biol Trace Elem Res. 2018 Oct;185(2):424-432. doi: 10.1007/s12011-018-1270-9. Epub 2018 Feb 21.

Selenium-Enriched Saccharomyces cerevisiae Reduces the Progression of Colorectal Cancer.

Author information

1
Department of Biology, Faculty of Science, Urmia University, Urmia, Iran.
2
Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Urmia University of Medical Science, Nazloo Street, P.O. Box 57147-83734, Urmia, Iran. vakili.maedeh@gmail.com.
3
Department of Pathology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran.
4
Department of Pathobiology and Quality control, Artemia and Aquatic Animals Research Institute, Urmia University, Urmia, Iran.
5
Branch for North-West and West region, Agricultural Biotechnology Research Institute of Iran, Tabriz, Iran.
6
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Yarikhosroushahia@tbzmed.ac.ir.
7
Department of Medical Nanotechnology, Faculty of Advanced Medical Science, Tabriz University of Medical Sciences, Daneshgah Street, P.O.Box 51548-53431, Tabriz, Iran. Yarikhosroushahia@tbzmed.ac.ir.

Abstract

Colorectal cancer is one of the most common causes of mortality in the world while malnutrition is responsible for one third of the problem. Selenium has been recommended for prevention of colorectal cancer. The present study was conducted to investigate the effect of selenium-enriched Saccharomyces cerevisiae in reducing colorectal cancer progression in rats. Five groups of 170-200-g weight rats (n = 40) including healthy and cancer controls, Saccharomyces cerevisiae, selenium, and selenium-enriched Saccharomyces cerevisiae-treated groups were examined. All animals except healthy control group received 40 mg 1,2-dimethylhydrazine (DMH) per kilogram weight of rat twice a week. The healthy group received normal saline, and synchronously, selenium group received soluble selenium (4 mg/mL), Saccharomyces cerevisiae and selenium-enriched groups received yeast with the density of 5 × 108 CFU/mL by daily gavage. All treatments were carried out for 5 weeks after the last injection. Animals were autopsied, and aberrant crypt foci (ACF) of ejected colon were studied in the 40th week. Microscopic sections were prepared for hematoxylin and eosin. Furthermore, immunohistochemical staining of CD31, BCL2, and P53 antibodies was performed. Macroscopic and microscopic evaluations showed that DMH had the least destructive effect in selenium-enriched Saccharomyces cerevisiae group compared to other groups. Selenium-enriched Saccharomyces cerevisiae reduces colorectal cancer progression by various mechanisms such as reduction in the number and size of ACF and alteration in the function of the proteins such as P53, BCL2, and CD31.

KEYWORDS:

Colorectal cancer; Dimethyl hydrazine; Saccharomyces cerevisiae; Selenium

PMID:
29468612
DOI:
10.1007/s12011-018-1270-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center